Michigan residents will be included in a major clinical trial through the participation of Spectrum Health.

The study will focus on peripheral arterial disease (PAD), which can lead to leg amputations, and will look at how a patient's own stem cells can be used in treatment.

Spectrum is one of up to 20 locations around the country but the only health system in Michigan to take part, which means some patients from Spectrum could be part of the study. Patients will have to meet certain requirements to be included.

Developing PAD means blood flow to the legs has been reduced by extra cholesterol and fat in the blood. One on 20 of Americans over the age of 50 have the condition.

The study, sponsored by Biomet Biologics, will test the effectiveness of the MarrowStim™ P.A.D. Kit.